Clinical ophthalmology (Auckland, N.Z.) · 2025
Systemic Immunomodulatory Therapy in Uveitis Related to Behçet's Disease: A 10-year Profile.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Almeida Mariana, Ferreira Ana Margarida, Araújo Joana R, Figueira Luís
Аннотация
PURPOSE: Behçet's disease (BD) is a systemic vasculitis which is often accompanied by intraocular inflammation. This study aims to determine the efficacy and safety of systemic immunomodulatory therapy (IMT) in Behçet's disease and the optimal timing for its discontinuation in patients who are in remission.
PATIENTS AND METHODS: A retrospective single center longitudinal study was performed at the Centro Hospitalar Universitário São João (Porto, Portugal). A total of 38 records of patients with uveitis related to BD and on IMT were analyzed for demographic data, characteristics of their uveitis, treatment period, pattern of relapses, and first and final discontinuation outcomes. The statistical analyses were done with IBM SPSS® software.
RESULTS: The mean follow-up duration was 122.5 ± 62.6 months. Anterior uveitis was the most common manifestation (36.8%), followed by retinal vasculitis (31.6%) and panuveitis (13.2%). Azathioprine (36.8%) and cyclosporine (28.9%) were the most used immunomodulatory agents. The median treatment duration was 63.5 months, significantly reducing relapse rates from 2 ± 2.0 to 1 ± 1.2 per year (p < 0.001). Biologic therapies showed a slight advantage in reducing relapses (p = 0.045). Among 16 patients (42.1%) who discontinued treatment, 30.8% experienced relapse after a median of 13 months. Patients treated for more than 6 years had no relapses.
CONCLUSION: IMT effectively controls ocular inflammation in BD uveitis, significantly reducing relapse frequency. Azathioprine and cyclosporine remain first-line therapies. Discontinuing IMT after 4-6 years of sustained remission appears to be a safe strategy, particularly after 6 years.
PATIENTS AND METHODS: A retrospective single center longitudinal study was performed at the Centro Hospitalar Universitário São João (Porto, Portugal). A total of 38 records of patients with uveitis related to BD and on IMT were analyzed for demographic data, characteristics of their uveitis, treatment period, pattern of relapses, and first and final discontinuation outcomes. The statistical analyses were done with IBM SPSS® software.
RESULTS: The mean follow-up duration was 122.5 ± 62.6 months. Anterior uveitis was the most common manifestation (36.8%), followed by retinal vasculitis (31.6%) and panuveitis (13.2%). Azathioprine (36.8%) and cyclosporine (28.9%) were the most used immunomodulatory agents. The median treatment duration was 63.5 months, significantly reducing relapse rates from 2 ± 2.0 to 1 ± 1.2 per year (p < 0.001). Biologic therapies showed a slight advantage in reducing relapses (p = 0.045). Among 16 patients (42.1%) who discontinued treatment, 30.8% experienced relapse after a median of 13 months. Patients treated for more than 6 years had no relapses.
CONCLUSION: IMT effectively controls ocular inflammation in BD uveitis, significantly reducing relapse frequency. Azathioprine and cyclosporine remain first-line therapies. Discontinuing IMT after 4-6 years of sustained remission appears to be a safe strategy, particularly after 6 years.